Article Text

Download PDFPDF
Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group
  1. D. S. Alberts*,
  2. C. Jiang,
  3. P. Y. Liu,
  4. S. Wilczynski,
  5. M. Markman§ and
  6. M. L. Rothenberg
  1. * Arizona Cancer Center, University of Arizona, Tucson, AZ
  2. Statistical Center, Southwest Oncology Group, Fred Hutchinson Cancer Research Center, Seattle, WA
  3. Department of Anatomical Pathology, City of Hope, Duarte, CA
  4. § Cleveland Clinic Cancer Center, Cleveland, OH
  5. Division of Medical Oncology, Vanderbilt University Medical Center, Nashville, TN
  1. Address correspondence and reprint requests to: David S. Alberts, MD, University of Arizona Cancer Center, 1515 North Campbell Avenue, P.O. Box 245024, Tucson, AZ 85724-5024. E-mail: dalberts{at}azcc.arizona.edu.

Abstract

Objective This report provides follow-up progression-free survival (PFS) and median survival data for women who achieved clinical complete remission (cCR) from stage III ovarian cancer after first-line therapy and were treated with altretamine consolidation therapy.

Methods Patients who enrolled in the SWOG 9326 study from September 1993 to July 1997 were required to have documented cCR from stage III ovarian cancer following front-line platinum-based therapy. Treatment consisted of 6 months of oral altretamine at 260 mg/m2/day for 14 consecutive days of a 28-day cycle.

Results Ninety-seven of 112 enrolled patients were evaluable for efficacy. This report presents median 6.2-year follow-up, dating from study registration. Median PFS was 28 (95% CI: 19–43) months. Median PFS for patients with optimal disease was 45 (95% CI: 27–48) months and for patients with suboptimal disease was 17 (95% CI: 12–26) months. Twenty-six of 61 (43%) patients with optimally debulked lesions and 5 of 36 (14%) patients with suboptimally debulked lesions remained disease free. Median survival of patients with optimally debulked disease has not been reached; median survival of patients with suboptimally debulked disease was 39 (95% CI: 19–51) months. No treatment-related adverse events were reported during the follow-up period.

Conclusions Consolidation therapy with oral altretamine was generally well tolerated and associated with prolonged progression-free and overall survival in the Phase II setting.

  • altretamine
  • consolidation therapy
  • hexamethylmelamine
  • ovarian cancer

Statistics from Altmetric.com

Footnotes

  • Reprint requests to: Southwest Oncology Group Operations Office (SWOG-9326), 14980 Omicron Drive, San Antonio, TX 78245-3217.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.